[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR078507A1 - Compuestos lipidicos, composiciones farmaceuticas, usos y metodo de preparacion - Google Patents

Compuestos lipidicos, composiciones farmaceuticas, usos y metodo de preparacion

Info

Publication number
AR078507A1
AR078507A1 ARP100101568A ARP100101568A AR078507A1 AR 078507 A1 AR078507 A1 AR 078507A1 AR P100101568 A ARP100101568 A AR P100101568A AR P100101568 A ARP100101568 A AR P100101568A AR 078507 A1 AR078507 A1 AR 078507A1
Authority
AR
Argentina
Prior art keywords
group
lipid compound
compound according
solvate
pharmaceutically acceptable
Prior art date
Application number
ARP100101568A
Other languages
English (en)
Inventor
Morten Braendvang
Ragnar Hovland
Anne Kristin Holmeide
Tore Skjaeret
Original Assignee
Pronova Biopharma Norge As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43050039&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR078507(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pronova Biopharma Norge As filed Critical Pronova Biopharma Norge As
Publication of AR078507A1 publication Critical patent/AR078507A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/26—Oxygen atoms attached in position 2 with hetero atoms or acyl radicals directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/03—Monocarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/347—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups
    • C07C51/367—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups by introduction of functional groups containing oxygen only in singly bound form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/60—Unsaturated compounds containing ether groups, groups, groups, or groups the non-carboxylic part of the ether being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/31—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by introduction of functional groups containing oxygen only in singly bound form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C07C69/675—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids of saturated hydroxy-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C07C69/675—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids of saturated hydroxy-carboxylic acids
    • C07C69/68—Lactic acid esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C07C69/708—Ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Reivindicacion 1: Un compuesto lipídico caracterizado porque responde a la formula (1) R1-O-C(R2)(R3)-X, donde R1 es un grupo alquilo C10-22, alquenilo C10-22 que tiene 1-6 uniones dobles, o un grupo alquinilo C10-22 que tiene 1-6 uniones triples; R2 y R3 son iguales o diferentes y se seleccionan entre un átomo de hidrogeno, un grupo hidroxi, un grupo alquilo, un átomo de halogeno, un grupo alcoxi, aciloxi, acilo, alquenilo, alquinilo, arilo, alquiltio, alcoxicarbonilo, carboxi, alquilsulfinilo, alquilsulfonilo, amino, y un grupo alquilamino, con la condicion de que R2 y R3 no son ambos un átomo de hidrogeno; o R2 y R3 juntos forman un grupo cicloalquilo; y X es un ácido carboxílico o derivado del mismo, o una sal aceptable farmacéuticamente, solvato, solvato de dicha sal, o una prodroga del mismo. Reivindicacion 41: Una composicion farmacéutica, caracterizada porque comprende al menos un compuesto lipídico de acuerdo con cualquiera de las reivindicaciones 1-40. Reivindicacion 42: Una composicion farmacéutica de acuerdo con la reivindicacion 41, caracterizada porque además comprende un vehículo, excipiente o diluyente farmacéuticamente aceptable, o cualquier combinacion de los mismos. Reivindicacion 71: El uso de al menos un compuesto de acuerdo con cualquiera de las reivindicaciones 1-40, caracterizado porque es para la prevencion o el tratamiento de una inflamacion. Reivindicacion 86: Un método para la produccion de un compuesto lipídico de acuerdo con la reivindicacion 1, caracterizado porque comprende: a) hacer reaccionar R1-OH con (LG)(R3)C(R2)(X), en donde LG es un grupo saliente; y b) aislar el compuesto lipídico.
ARP100101568A 2009-05-08 2010-05-07 Compuestos lipidicos, composiciones farmaceuticas, usos y metodo de preparacion AR078507A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17650309P 2009-05-08 2009-05-08

Publications (1)

Publication Number Publication Date
AR078507A1 true AR078507A1 (es) 2011-11-16

Family

ID=43050039

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP100101568A AR078507A1 (es) 2009-05-08 2010-05-07 Compuestos lipidicos, composiciones farmaceuticas, usos y metodo de preparacion
ARP170102752A AR109789A2 (es) 2009-05-08 2017-10-03 Compuestos lipídicos

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP170102752A AR109789A2 (es) 2009-05-08 2017-10-03 Compuestos lipídicos

Country Status (29)

Country Link
US (2) US8735436B2 (es)
EP (1) EP2427415B1 (es)
JP (2) JP5843755B2 (es)
KR (1) KR101783817B1 (es)
CN (1) CN102459142B (es)
AR (2) AR078507A1 (es)
AU (1) AU2010244136B2 (es)
BR (1) BRPI1015120B8 (es)
CA (1) CA2760877C (es)
CL (1) CL2011002745A1 (es)
CO (1) CO6430454A2 (es)
DK (1) DK2427415T3 (es)
EA (1) EA021177B1 (es)
ES (1) ES2726765T3 (es)
HR (1) HRP20190732T1 (es)
IL (1) IL216171A (es)
MA (1) MA33341B1 (es)
MX (2) MX2011011614A (es)
MY (1) MY165292A (es)
NZ (2) NZ618734A (es)
PH (1) PH12015500930A1 (es)
PL (1) PL2427415T3 (es)
PT (1) PT2427415T (es)
SG (1) SG175401A1 (es)
TR (1) TR201905768T4 (es)
TW (1) TWI558395B (es)
UA (1) UA109528C2 (es)
WO (1) WO2010128401A1 (es)
ZA (2) ZA201108163B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2733353T3 (es) 2007-11-09 2019-11-28 Basf As Compuestos lípidos para uso en productos cosméticos, como suplemento alimenticio o como un medicamento
NZ588603A (en) 2008-03-26 2012-03-30 Oramed Ltd Methods and compositions for oral administration of a protein of up to 100000 Daltaons, a first protease inhibitor and a second protease inhibitor wherein said protease inhibitors inhibit trypsin
EP2147910A1 (en) 2008-07-15 2010-01-27 Pronova BioPharma Norge AS Novel lipid compounds
AR078507A1 (es) 2009-05-08 2011-11-16 Pronova Biopharma Norge As Compuestos lipidicos, composiciones farmaceuticas, usos y metodo de preparacion
EP2493328A1 (en) 2009-10-30 2012-09-05 Tharos Ltd. Solvent-free process for obtaining phospholipids and neutral enriched krill oils
GB201014633D0 (en) * 2010-09-02 2010-10-13 Avexxin As Rheumatoid arthritis treatment
WO2012059818A1 (en) * 2010-11-05 2012-05-10 Pronova Biopharma Norge As Methods of treatment using lipid compounds
WO2014083528A2 (en) * 2012-12-02 2014-06-05 Mahesh Kandula Compositions and methods for the treatment of cardiovascular diseases and lipid disorders
EP4215205A1 (en) 2013-01-03 2023-07-26 Oramed Ltd. Methods and compositions for treating nafld, hepatic steatosis, and sequelae thereof
WO2014132135A2 (en) * 2013-02-28 2014-09-04 Pronova Biopharma Norge As Methods of preparing fatty acid derivatives
US11351139B2 (en) * 2013-02-28 2022-06-07 Basf As Composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same
GB201409363D0 (en) 2014-05-27 2014-07-09 Avexxin As Skin cancer treatment
JP7341916B2 (ja) * 2015-04-01 2023-09-11 ビーエーエスエフ エーエス アポｃ３を低下させるためのチアオキソ化合物の使用
RU2705991C2 (ru) * 2015-04-01 2019-11-13 Пронова Биофарма Норге Ас Применение тиаоксосоединений для уменьшения содержания аро с3
US20180104201A1 (en) 2015-04-28 2018-04-19 Pronova Biopharma Norge As Use of structurally enhanced fatty acids containing sulphur for preventing and or treating non alcoholic steatohepatitis
GB201521085D0 (en) * 2015-11-30 2016-01-13 Biozep As Use
GB201604316D0 (en) 2016-03-14 2016-04-27 Avexxin As Combination therapy
KR20190055153A (ko) 2016-09-21 2019-05-22 아벡신 에이에스 약학 조성물
IL270676B2 (en) 2017-05-16 2024-11-01 Ability Pharmaceuticals S L A pharmaceutical combination containing a polyunsaturated fatty acid and a chemotherapy agent for the treatment of cancer
WO2019083816A1 (en) 2017-10-23 2019-05-02 Epitracker, Inc. FATTY ACID ANALOGUES AND THEIR USE IN THE TREATMENT OF STATES RELATED TO METABOLIC SYNDROME
EP3720431B1 (en) 2017-12-06 2024-10-30 Basf As Fatty acid derivatives for treating non-alcoholic steatohepatitis
EP3793560A4 (en) * 2018-05-16 2022-03-23 Epitracker, Inc. COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF AGING-RELATED CONDITIONS
JP2021525249A (ja) 2018-05-23 2021-09-24 エピトラッカー インコーポレイテッドＥｐｉｔｒａｃｋｅｒ， Ｉｎｃ． 加齢及び長期性の質に関連する状態の診断及び治療のための組成物及び方法
KR20210015883A (ko) 2018-05-23 2021-02-10 노스씨 테라퓨틱스 비.브이. 당뇨 제어 및 염증성장질환 치료의 향상을 위한 구조적으로 변형된 지방산
MX2021003750A (es) * 2018-10-11 2021-06-15 Basf As Compuestos aromaticos y usos farmaceuticos de los mismos.
CN114269745A (zh) 2019-07-29 2022-04-01 海帕瑞吉尼克斯股份有限公司 用于促进肝再生或减少或预防肝细胞死亡的杂芳基取代的吡唑并吡啶蛋白激酶抑制剂
JP2023511297A (ja) 2020-01-15 2023-03-17 ヘパリジェニックス ゲーエムベーハー 肝再生促進又は肝細胞死の抑制もしくは防止のためのプロテインキナーゼ阻害剤
JP2023554524A (ja) 2020-12-22 2023-12-27 ノースシー セラピューティクス ベスローテン フェンノートシャップ 非アルコール性脂肪性肝炎の治療のための酸素含有構造強化脂肪酸を含む組合せ療法

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909554A (en) 1956-07-23 1959-10-20 Monsanto Chemicals Process for the manufacture of (alkylmercapto) alkyl sulfates
GB1038723A (es) 1962-03-26
US4040781A (en) 1974-06-06 1977-08-09 Lever Brothers Company Novel 2-(alkylsulfinyl)ethyl sulfates and compositions employing same
US4032564A (en) * 1974-09-09 1977-06-28 Zoecon Corporation Esters of cyclopropylalkanols
GB1523276A (en) 1974-09-20 1978-08-31 Lafon Labor Sulphur-containing amino compounds
US4009211A (en) 1975-07-29 1977-02-22 Gulf Research & Development Company Beta,beta-dialkylethylmercaptoethoxylate as new compounds
US4209410A (en) 1976-04-28 1980-06-24 Phillips Petroleum Company Lubricants
EP0002007B1 (de) 1977-11-11 1982-07-28 Ciba-Geigy Ag Neue Pyridindicarbonsäureesterderivate und ihre Gemische mit metallhaltigen Stabilisatoren sowie ihre Verwendung zur Stabilisierung von chlorhaltigen Thermoplasten
JPS5570841A (en) 1978-11-24 1980-05-28 Konishiroku Photo Ind Co Ltd Forming method of dye image
US4368190A (en) 1980-04-17 1983-01-11 Merck & Co., Inc. Immunologically active dipeptidyl 4-O-,6-O-acyl-2-amino-2-deoxy-D-glucose derivatives and methods for their preparation
DE3164332D1 (en) 1980-10-21 1984-07-26 Boehringer Mannheim Gmbh Phospholipids that contain sulphur, process for their preparation and medicines containing these compounds
US4411808A (en) 1982-08-04 1983-10-25 Exxon Research & Engineering Co. Multifunctional additive for power transmission shift fluids
JPS6176438A (ja) * 1984-09-20 1986-04-18 Canon Inc 乳酸誘導体
US4775223A (en) * 1984-09-20 1988-10-04 Canon Kabushiki Kaisha Lactic acid derivative, liquid crystal composition containing same and liquid crystal device
CA2010000A1 (en) 1989-04-07 1990-10-07 Paul B. Merkel Photographic recording material containing a cyan dye-forming coupler
JPH0451149A (ja) 1990-06-19 1992-02-19 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料
FR2663928B1 (fr) 1990-06-27 1994-04-08 Norsolor Nouveaux composes acryliques soufres, un procede pour leur preparation et leur application a la synthese de nouveaux polymeres.
EP0487809A1 (en) 1990-11-28 1992-06-03 Monsanto Europe S.A./N.V. Rubber compositions having improved processability and improved rubber-vulcanisate properties
JPH0543529A (ja) 1991-08-10 1993-02-23 Taisho Pharmaceut Co Ltd アルカンアミドアンモニウム化合物
JP2755279B2 (ja) 1992-03-19 1998-05-20 三井化学株式会社 熱可塑性樹脂組成物およびその成形体
JP2793458B2 (ja) 1992-03-19 1998-09-03 三井化学株式会社 コネクター用ポリアミド系樹脂組成物およびコネクター
AU7044894A (en) 1993-06-10 1995-01-03 University Of North Carolina At Chapel Hill, The (phospho)lipids for combatting hepatitis b virus infection
JP3110918B2 (ja) 1993-06-18 2000-11-20 富士写真フイルム株式会社 ハロゲン化銀写真感光材料
US5523430A (en) * 1994-04-14 1996-06-04 Bristol-Myers Squibb Company Protein farnesyl transferase inhibitors
GB2290789B (en) 1994-07-01 1998-09-16 Ciba Geigy Ag Titanium and zirconium complexes of carboxylic acids as corrosion inhibitors
WO1996011908A1 (en) * 1994-10-13 1996-04-25 Peptide Technology Limited Modified polyunsaturated fatty acids
US7517858B1 (en) 1995-06-07 2009-04-14 The Regents Of The University Of California Prodrugs of pharmaceuticals with improved bioavailability
FR2741619B1 (fr) 1995-11-28 1998-02-13 Pf Medicament Nouveaux derives de 2,3,5-trimethyl-4-hydroxy-anilides, leur preparation et leur application en therapeutique
EP0904072A4 (en) * 1996-04-12 2003-07-30 Peptide Technology Pty Ltd METHODS FOR TREATING IMMUNOPATHOLOGIES USING POLYUNSATURATED FATTY ACIDS
US6060515A (en) * 1997-01-24 2000-05-09 The Regents Of The University Of California Treatment of skin conditions by use of PPARα activators
CA2278123A1 (en) * 1997-01-24 1998-07-30 Karen Hanley Use of fxr, ppar.alpha. and lxr.alpha. activators to restore barrier function, promote epidermal differentiation and inhibit proliferation
WO1999016801A1 (en) * 1997-10-01 1999-04-08 The Procter & Gamble Company Glyoxylic compound comprising one or more active ingredient
JPH11180929A (ja) 1997-12-19 1999-07-06 Asahi Glass Co Ltd エステル誘導体
WO1999058120A1 (en) 1998-05-08 1999-11-18 Rolf Berge USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS
FR2786187B1 (fr) 1998-11-19 2001-11-09 Univ Paris Curie Composes du type 2-acylamino-2-deoxy-glucono-1,5-lactone, procede d'obtention, compositions les comportant et utilisations
FR2792312B1 (fr) 1999-04-15 2001-06-08 Oreal Composes (poly)thia-alcynoiques et leurs derives, compositions les comprenant et leur utilisation
US6723717B1 (en) 1999-06-01 2004-04-20 The University Of Texas Southwestern Medical Center Sulfur-containing thyroxane derivatives and their use as hair growth promotors
WO2000072920A1 (en) 1999-06-01 2000-12-07 The University Of Texas Southwestern Medical Center Substituted biaryl ether compounds
NO328803B1 (no) 2000-03-03 2010-05-18 Thia Medica Nye fettsyreanaloger
WO2001090087A1 (fr) * 2000-05-26 2001-11-29 Nippon Shinyaku Co., Ltd. Composes heterocycliques
UA75083C2 (uk) 2000-06-22 2006-03-15 Тераванс, Інк. Похідні глікопептидфосфонатів
FR2828487B1 (fr) 2001-08-09 2005-05-27 Genfit S A Nouveaux composes derives d'acides gras, preparation et utilisations
AU2002361850A1 (en) 2001-12-21 2003-07-30 3M Innovative Properties Company Medicinal aerosol formulations comprising ion pair complexes
GB2383355A (en) 2001-12-22 2003-06-25 Schlumberger Holdings An aqueous viscoelastic fluid containing hydrophobically modified polymer and viscoelastic surfactant
MXPA04007382A (es) 2002-01-31 2004-10-11 Tfl Ledertechnik Gmbh Composiciones y su uso para impartir repelencia al agua a cuero o pieles, textiles y otros materiales fibrosos.
CA2493690C (en) 2002-06-13 2011-11-08 New York University Synthetic c-glycolipid and its use for treating cancer, infectious diseases and autoimmune diseases
FR2845991B1 (fr) 2002-10-16 2005-02-04 Pf Medicament Derives d'alpha-phenyl acetanilides et leur application en therapeutique humaine
US8372430B2 (en) 2002-12-17 2013-02-12 The Procter & Gamble Company Compositions, methods, and kits useful for the alleviation of gastrointestinal effects
EP1600438A4 (en) 2003-02-28 2007-05-02 Kaneka Corp METHODS FOR PRODUCING OPTICALLY ACTIVE COMPOUNDS COMPRISING SUBSTITUENTS IN POSITION 2
DE10326303A1 (de) 2003-06-11 2004-12-30 Celares Gmbh Reagenzien zur Modifikation von Biopharmazeutika, deren Herstellung und Anwendung
JP2007522118A (ja) * 2004-01-30 2007-08-09 ペプリン バイオリピッズ ピーティーワイ エルティーディー 治療用分子および担体分子
JP4563114B2 (ja) 2004-08-30 2010-10-13 出光興産株式会社 潤滑剤用添加剤
WO2006109491A1 (ja) 2005-03-31 2006-10-19 Yamaguchi University 波力エネルギー変換装置
CN101213281B (zh) * 2005-05-04 2013-03-13 普罗诺瓦生物医药挪威公司 新的dha衍生物及其作为药物的用途
BRPI0611159A2 (pt) 2005-05-04 2012-07-31 Pronova Biopharma Norge As composto e respectivo processo e fabrico, composiÇÕes farmacÊutica e de Ácido graxo, usos de composto e mÉtodos de controle da reduÇço do peso corpàreo e/ou prevenÇço do ganho de peso corpàreo, de tratamento e/ou prevenÇço da obesidade ou de uma condiÇço de sobrepeso, do diabete, de doenÇas relacionadas com a amiloidose, de tratamento ou profilaxia de fatores méltiplos de risco para doenÇas cardiovasculares e de prevenÇço do derrame cerebral, de ataques isquÊmicos cerebrais ou passageiros relacionados com a aterosclerose de vÁrias artÉrias
US20070167529A1 (en) 2006-01-17 2007-07-19 Walton Rebecca A Antimicrobial compositions for treating fabrics and surfaces
WO2007116027A1 (en) 2006-04-12 2007-10-18 Unilever Plc Oral composition comprising a polyunsaturated fatty acid and salicylic acid for obtaining an antiinflammatory effect in skin
EP1849449A1 (en) 2006-04-26 2007-10-31 3M Innovative Properties Company Filler containing composition and process for production and use thereof
US7763607B2 (en) 2006-04-27 2010-07-27 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators
CA2652235A1 (en) 2006-05-09 2007-11-22 Hemaquest Pharmaceuticals, Inc. Methods for treating blood disorders
KR101438177B1 (ko) * 2006-11-01 2014-09-05 프로노바 바이오파마 너지 에이에스 페록시솜 증식자-활성화 수용체의 활성자 또는 조절자인 알파-치환된 오메가-3 지질
WO2008053340A1 (en) * 2006-11-03 2008-05-08 Pronova Biopharma Norge As A combination product comprising at least one lipid substituted in the alpha position and at least one hypoglycemic agent
CN101225064A (zh) 2007-01-19 2008-07-23 上海汇瑞生物科技有限公司 一种制备β-硫杂-α-烷基脂肪酸的新方法
DE102007017179A1 (de) * 2007-04-12 2008-10-23 Clariant International Ltd. Verfahren zur Herstellung von Alkylpolyglykolcarbonsäuren und Polyglykoldicarbonsäuren mittels Direktoxidation
EP2205074A4 (en) * 2007-10-04 2013-07-31 Harvard College ANALOGUES OF THE MOENOMYCIN, METHODS OF SYNTHESIS AND USES THEREOF
JP5575651B2 (ja) * 2007-10-31 2014-08-20 プロノヴァ バイオファーマ ノルゲ アーエス 新規のｄｈａ誘導体およびその医薬品としての用途
ES2733353T3 (es) 2007-11-09 2019-11-28 Basf As Compuestos lípidos para uso en productos cosméticos, como suplemento alimenticio o como un medicamento
WO2009149496A1 (en) 2008-06-10 2009-12-17 Central Northern Adelaide Health Service Treatment of diabetes and complications thereof and related disorders
FR2933006B1 (fr) 2008-06-27 2010-08-20 Inst Francais Du Petrole Solution absorbante contenant un inhibiteur de degradation soufre a groupement carboxyle et methode pour limiter la degradation d'une solution absorbante
EP2315740B1 (en) 2008-07-08 2017-10-25 Catabasis Pharmaceuticals, Inc. Fatty acid acetylated salicylates and their uses
EP2147910A1 (en) * 2008-07-15 2010-01-27 Pronova BioPharma Norge AS Novel lipid compounds
AR078507A1 (es) * 2009-05-08 2011-11-16 Pronova Biopharma Norge As Compuestos lipidicos, composiciones farmaceuticas, usos y metodo de preparacion
MX2012002710A (es) 2009-09-01 2012-04-19 Catabasis Pharmaceuticals Inc Conjugados de niacina y acidos grasos y sus usos.
EP2526084A1 (en) 2010-01-20 2012-11-28 Pronova BioPharma Norge AS Salicylate fatty acid derivatives
WO2012059818A1 (en) 2010-11-05 2012-05-10 Pronova Biopharma Norge As Methods of treatment using lipid compounds
WO2012115695A1 (en) 2011-02-25 2012-08-30 Catabasis Pharmaceuticals, Inc. Bis-fatty acid conjugates and their uses
WO2013016531A2 (en) 2011-07-26 2013-01-31 Purdue Research Foundation Compounds and methods for use in treating neoplasia and cancer

Also Published As

Publication number Publication date
US20140221439A1 (en) 2014-08-07
TW201106946A (en) 2011-03-01
EP2427415A1 (en) 2012-03-14
NZ596386A (en) 2014-01-31
KR101783817B1 (ko) 2017-10-23
PT2427415T (pt) 2019-05-31
MY165292A (en) 2018-03-21
BRPI1015120A2 (pt) 2019-04-09
JP2012526094A (ja) 2012-10-25
CL2011002745A1 (es) 2012-07-27
ZA201303962B (en) 2014-02-26
HRP20190732T1 (hr) 2019-06-14
PH12015500930B1 (en) 2016-10-17
CO6430454A2 (es) 2012-04-30
IL216171A0 (en) 2012-01-31
UA109528C2 (uk) 2015-09-10
SG175401A1 (en) 2011-12-29
ZA201108163B (en) 2018-11-28
US8735436B2 (en) 2014-05-27
AR109789A2 (es) 2019-01-23
CA2760877A1 (en) 2010-11-11
AU2010244136B2 (en) 2016-05-12
TWI558395B (zh) 2016-11-21
NZ618734A (en) 2015-01-30
BRPI1015120B8 (pt) 2022-02-15
EP2427415A4 (en) 2015-07-22
CA2760877C (en) 2020-09-08
AU2010244136A1 (en) 2011-11-17
EA201171371A1 (ru) 2012-05-30
CN102459142B (zh) 2017-08-08
CN102459142A (zh) 2012-05-16
JP5843755B2 (ja) 2016-01-13
IL216171A (en) 2015-03-31
KR20120016263A (ko) 2012-02-23
JP2016026146A (ja) 2016-02-12
MA33341B1 (fr) 2012-06-01
PH12015500930A1 (en) 2016-10-17
WO2010128401A9 (en) 2011-12-08
WO2010128401A1 (en) 2010-11-11
MX2011011614A (es) 2011-11-18
US20120122940A1 (en) 2012-05-17
ES2726765T3 (es) 2019-10-09
DK2427415T3 (da) 2019-06-11
BRPI1015120B1 (pt) 2021-09-14
EP2427415B1 (en) 2019-03-20
EA021177B1 (ru) 2015-04-30
TR201905768T4 (tr) 2019-05-21
MX366137B (es) 2019-06-28
PL2427415T3 (pl) 2019-09-30

Similar Documents

Publication Publication Date Title
AR078507A1 (es) Compuestos lipidicos, composiciones farmaceuticas, usos y metodo de preparacion
CL2022001625A1 (es) Derivados de pirazolilo útiles como agentes anti-cancerígenos
CU20110235A7 (es) Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17
CY1119727T1 (el) Ενωσεις και συνθεσεις για τη θεραπεια παρασιτικων νοσων
CY1120826T1 (el) Τριυποκατεστημενα παραγωγα βενζοτριαζολης ως αναστολεις διϋδροοροτικης οξυγενασης
UY32490A (es) Inhibidores de beta-secretasa
NO20080865L (no) Spirokromanonderivater som acetyl-koenzym-A-karboksylase(ACC)inhibitorer
TR201802944T4 (tr) İlaç olarak azai̇ndazol veya di̇azai̇ndazol türünün türevleri̇
CO6690768A2 (es) Derivados de triazina-oxadiazoles, útiles como inhibidores de los canales de sodio navi.7
CL2012001911A1 (es) Compuestos derivados de fumarato; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad inflamatoria o neurodegenerativa.
EA201101672A1 (ru) Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина
PA8827901A1 (es) Derivados de quinoxalin- y quinolin-carboxamida
UY31885A (es) Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones.
DOP2014000121A (es) Derivados de betulina
UY33075A (es) Derivados de ciclohexano y usos de los mismos
MX2011010415A (es) Formulaciones farmaceuticas que comprenden derivados de nitrocatecol y metodos para hacer las mismas.
CY1118541T1 (el) D2 αποκλειστες, μεθοδοι συνθεσης και μεθοδοι χρησης
EA201200471A1 (ru) Простые эфирные производные бициклических гетероарилов
MX2019006165A (es) Proceso para la preparacion de derivados del acido biliar de las sulfonilureas.
PH12015501752A1 (en) Substituted bisphenyl butanoic phosphonic acid derivatives as nep inhibitors
CY1119710T1 (el) Συντηγμενες θειαζολο- και οξαζολο-πυριμιδινονες
EA201391524A1 (ru) Производные гликозида и их применение
UY32055A (es) Derivados sustituidos de la 5-Halo-N2-[sustituido](1-metil-1H-imidazol-4-il)pirimidin-2,-diamina y sus sales farmacéuticamente aceptables, procesos de preparación, composiciones y aplicaciones.
ECSP10010597A (es) Nueva clase de espiro piperidinas para el tratamiento de enfermedades neurodegenerativas
DOP2019000299A (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias

Legal Events

Date Code Title Description
FG Grant, registration